Recce Pharmaceuticals (RCE) H1 2026 earnings summary

Executive summary

• Focused on developing synthetic anti-infectives targeting antibiotic-resistant superbugs and emerging viral pathogens, with lead candidate RECCE® 327 advancing into human clinical trials.

• Significant R&D progress, including positive preclinical and clinical milestones, new patent grants, and ongoing global clinical trials.

• Received an Advanced Overseas Finding for up to A$85 million in eligible R&D expenditure.

• Loss of founder and technology inventor Dr. Graham JH Melrose in November 2025.

Financial highlights

• Operating loss for the half-year was $16.56 million, up from $7.74 million in the prior year, driven by increased R&D, share-based payments, and loan transaction costs.

• Revenue and other income totaled $7.02 million, primarily from R&D tax incentives and interest income.

• Net cash outflow from operating activities was $9.49 million, compared to $6.92 million in the prior year.

• Cash and cash equivalents at period end were $0.37 million, down from $10.45 million at June 2025.

• No dividends declared or paid during the period.

Outlook and guidance

• Ongoing focus on progressing RECCE® 327 through clinical trials and securing additional funding through equity, loans, and R&D tax rebates.

• Management confident in ability to raise further capital and reduce cash burn if necessary.